![carlo traverso genova carlo traverso genova](http://www.studiorosina.eu/wp/wp-content/uploads/2017/11/Giovanni_Traverso_big.jpg)
![carlo traverso genova carlo traverso genova](https://www.pittoriliguri.info/2020/wp-content/uploads/2020/10/s-l1600-38-1536x1152.jpg)
Imaculaweb turned out to be an effective tool to collect and share clinical data as well as to monitor patient outcome.Īflibercept Age-related macular degeneration Anti-VEGF Macular degeneration Optical coherence tomography Ranibizumab Real-life study Vascular endothelial growth factor. Traverso graduated from the Universita Degli Studi Di Genova Facolta Di Medicina E Chirurgia in 1979. Carlo TRAVERSO, Professor of Ophthalmology, Director of Eye Clinic, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova. CMT decreased significantly during the overall follow-up period, and intra- and subretinal fluid decreased (p < 0.0001). In the first year, 30% of the patients received at least 7 injections, while only 6.4% received <3 injections. The mean number of injections was 5.2, 2.6, and 2.3 at the 1-, 2-, and 3-year follow-ups, respectively. Significant VA increases (p = 0.0002 for the first year and p = 0.045 for the second year) were documented at years 1 and 2 but not at year 3 (p = 0.8). Carlo - Via Cinque Maggio 77/A - 16147 Genova (GE): visualizza indirizzo, numero di telefono, CAP, mappa, indicazioni stradali e altre informazioni utili per Traverso ING.
![carlo traverso genova carlo traverso genova](https://primaillevante.it/media/2021/08/tir-bloccato.jpg)
Visualizza il profilo di Carlo Traverso su LinkedIn, la pi grande comunit professionale al mondo. Guarda il profilo completo su LinkedIn e scopri i collegamenti di Carlo e le offerte di lavoro presso aziende simili. The mean VA was 49.4 ± 21.4, 54.1 ± 22.2, 51.6 ± 24.9, and 48.3 ± 25.7 letters at baseline and at the 1-, 2-, and 3-year follow-ups, respectively. Carlo ha indicato 2 esperienze lavorative sul suo profilo. In total, 126 eyes of 109 patients were included in the study. In this observational study based on the Imaculaweb registry, outcome measures were the number of injections, the change in mean visual acuity (VA) and central macular thickness (CMT), and the time between diagnosis and the first injection. The aim of this study is to assess and compare the long-term clinical efficacy of anti-VEGF drugs using the Imaculaweb registry.